Antimigraine medication use and associated health care costs in employed patients

Jun Wu · Mary D. Hughes · Matthew F. Hudson · Peggy J. Wagner

Abstract  Migraine is under diagnosed and suboptimally treated in the majority of patients, and also associated with decreased productivity in employees. The objective of this retrospective study is to assess the antimigraine medication use and associated resource utilization in employed patients. Patients with primary diagnosis of migraine or receiving antimigraine prescription drugs were identified from an employer-sponsored health insurance plan in 2010. Medical utilization and health care costs were determined for the year of 2010. Generalized linear regression was applied to evaluate the association between health care costs and the use of antimigraine medications by controlling covariates. Of 465 patients meeting the study criteria, nearly 30% that had migraine diagnosis were prescribed antimigraine medications, and 20% that had migraine diagnosis were not prescribed antimigraine medications. The remaining 50% were prescribed antimigraine medications but did not have migraine diagnosis. Patients with antimigraine medication prescriptions showed lower frequency of emergency department visits than those without antimigraine medication prescriptions. Regression models indicated an increase in migraine-related health care costs by 86% but decreases in all-cause medical costs and total health care costs by 42 and 26%, respectively, in the antimigraine medication use group after adjusting for covariates. Employed patients experienced inadequate pharmacotherapy for migraine treatment. After controlling for covariates, antimigraine prescription drug use was associated with lower total medical utilization and health care costs. Further studies should investigate patient self-reported care and needs to manage headache and develop effective intervention to improve patient quality of life and productivity.

Keywords  Migraine · Antimigraine medication use · Health care costs · Employed patients

Introduction

Migraine is a chronic condition characterized by moderate to severe headaches. About 29.5 million Americans suffer from migraine, with an estimated 18% of women and 6% men directly affected [1–3]. The predominate (or primary) age to experience migraines is between 25 and 55, which coincides with an individual’s most active employment period [4, 5]. Consequently, migraine-attributable morbidity may adversely affect work productivity via absenteeism or presenteeism (compromised work productivity in the course of daily labor) [6]. Additionally, migraine sufferers may also experience compromised rest and leisure that indirectly affects labor productivity, and directly exacerbates quality of life [7–9]. Studies suggest migraine-related morbidity, particularly, accounts for costs incurred
and health care costs differ between patients receiving sponsored health plan? (2) How do the resource utilization drug use pattern in patients enrolled in an employer-

This study was designed to answer the following two primary questions: (1) What is the antimigraine prescription drug use pattern in patients enrolled in an employer-sponsored health plan? (2) How do the resource utilization and health care costs differ between patients receiving prescription drugs to treat migraine and those not receiving prescription drugs?

Methods

Data source and patient selection

De-identified claims data based on an employer-sponsored health plan were extracted by Advisory Board Company in Washington D.C. All patients with at least one primary diagnosis of migraine between January 1, 2010 and December 31, 2010 were identified by International Classification of Diseases, 9th revision (ICD-9) (346.xx). All patients receiving at least one prescription for a medication to treat migraine between January 1, 2010 and December 31, 2010 were also identified by therapeutic category in the database (Table 1). Patients were required to be enrolled in the employer-sponsored health plan continuously during the year of 2010. Patients enrolled as dependents were excluded from the study. Given the bidirectional influence of migraine and major depression described in previous studies [22, 23], we considered comorbid depression if patients presented at least one primary diagnosis of major depression or received at least one prescription for an antidepressant or antianxiety medication shown in Table 1 during the study period. All eligible patients were divided into two groups: patients who received antimigraine medications and those who did not.

Medical utilization

Total medical utilization with any conditions within 1 year was evaluated by hospitalization frequency, emergency department (ED) visits, and total numbers of outpatient and physician office visits. Patients with at least one time hospitalization or ED visit during the study period were categorized as hospitalization or ED visit during the study period. Medical utilization related to migraine was identified by primary diagnosis codes (346.xx).

Health care costs

Health care costs were evaluated based on third party payer perspective. Reimbursement rates paid by the employer were used to compute annual total and migraine-related health care costs, including medical care and pharmacy costs. Medical care costs were defined as the sum of inpatient, ED, hospital outpatient, and physician office visit costs. Annual total health care costs were the sum of medical and pharmacy costs associated with any conditions during the 1-year study period. Migraine-related health care costs were identified by primary diagnosis code of
migraine (346.xx) for medical care costs and by prescription drugs to treat migraine for pharmacy costs. Total migraine-related health care costs were the sum of migraine-related medical and pharmacy costs during the 1-year study period.

Risk index (RI) and Care gap index (CGI) [24]

RI is an index value created by using D2Hawkeye risk modeling system to indicate the risk a member will become a catastrophic case, and is based on the number of comorbidities presented. Similarly, CGI is an index value indicating the degree to which a member complies with recommended care guidelines associated with their age and existing conditions. Both of these scores provided by the health insurance program are routinely used by a number of care management program directors and managers to identify specific patient groups that may particularly benefit from tailored care management programs. These two variables were included in our regression models as covariates for adjustment.

Data analysis

Univariate analyses were used to compare patient characteristics, unadjusted medical utilization, and health care costs between the two groups, namely, those using antimigraine medications and those not using antimigraine medications. Chi-square tests were applied to analyze categorical variables and t tests were used for continuous variables. Nonparametric tests (Wilcoxon rank-sum test) were used to compare various health care costs between two groups.

Generalized linear regressions with log link and gamma distribution were considered to analyze the associations between health care costs and the use of antimigraine medications after adjusting for diagnosis of migraine, age, gender, comorbid depression, CGI, and RI. The level of significance was preset at $\alpha = 0.05$. All statistical analyses were conducted by SAS 9.2 (SAS Institute, Cary, NC).

Results

Figure 1 and Table 2 display the patient selection and characteristics of our study population enrolled in an employer-sponsored health plan during the study period (January 1, 2011 to December 31, 2011). A total of 465 patients (5.9% of total employees enrolled in the employer-sponsored health insurance plan in 2010) met the study inclusion and exclusion criteria, with an average age of 43.5 years. Females accounted for nearly 95% of the study population; two-thirds of the patients had depression diagnosis or used antidepressants during the study period. Of the patients receiving antimigraine medications, 64% did not have migraine diagnosis. In contrast, 43% of patients diagnosed with migraines, did not take antimigraine medications.

Table 3 compared unadjusted medical utilization and health care costs between patients using and not using antimigraine medications. Patients receiving antimigraine medications evidenced 12.3 and 7.2% fewer all-cause and migraine-related ED visits, respectively, as compared to

### Table 1 Medications for migraine and depression used by participants

| Antimigraine medications                                      | Antidepressants                             |
|---------------------------------------------------------------|---------------------------------------------|
| Acetaminophen/caffeine/isometheptene mucate                   | Alprazolam                                  |
| Acetaminophen/dichlorphenazone/isometheptene mucate           | Alprazolam extended-release                 |
| Almotriptan malate                                            | Amitriptyline hydrochloride                |
| Dihydroergotamine mesylate                                    | Amitriptyline-chlordiazepoxide             |
| Eiletriptan hydrobromide                                      | Budeprion hydrochloride                    |
| Ergotamine-caffeine                                           | Budeprion hydrochloride extended-release   |
| Frovatriptan succinate                                        | Budeprion hydrochloride sustained-release  |
| Naratriptan hydrochloride                                     | Citalopram hydrobromide                    |
| Rizatriptan benzoate                                          | Clomipramine hydrochloride                 |
| Sumatriptan succinate                                         | Clorazepate dipotassium                    |
| Sumatriptan succinate/naproxen sodium                         | Desipramine hydrochloride                  |
| Zolmitriptan                                                  | Desvenlafaxine succinate                    |
|                                                              | Diazepam                                    |
|                                                              | Doxepin hydrochloride                       |
|                                                              | Duloxetine hydrochloride                   |
|                                                              | Escitalopram oxalate                       |
|                                                              | Fluoxetine hydrochloride                   |
|                                                              | Fluoxetine hydrochloride/olanzapine        |
|                                                              | Fluoxetine pamoate                         |
|                                                              | Imipramine hydrochloride                   |
|                                                              | Lorazepam                                  |
|                                                              | Mirtazapine                                 |
|                                                              | Nortriptyline hydrochloride                |
|                                                              | Oxazepam                                   |
|                                                              | Paroxetine hydrochloride                   |
|                                                              | Paroxetine mesylate                        |
|                                                              | Phenelzine sulfate                         |
|                                                              | Trazodone hydrochloride                    |
|                                                              | Venlafaxine hydrochloride                  |
|                                                              | Venlafaxine hydrochloride extended-release |

---

migraine (346.xx) for medical care costs and by prescription drugs to treat migraine for pharmacy costs. Total migraine-related health care costs were the sum of migraine-related medical and pharmacy costs during the 1-year study period.
those not receiving antimigraine medications. Groups using antimigraine medication also evidenced fewer outpatient and office visits. Pharmacy cost for antimigraine medication use accounted for 78% of total migraine-related costs. An increase in all-cause pharmacy cost by $1,010 and decrease in all-cause medical cost by $3,407 were shown in the antimigraine medication use group.

Table 4 presents associations between various health care costs and the use of migraine medications after adjusting for diagnosis of migraine, age, gender, CGI, RI, and comorbid depression. After translating the log-transformed coefficients based on generalized linear regressions, we found even though patients receiving antimigraine medications showed increased migraine-related health care costs by 86%, all-cause medical costs and total health care costs were reduced significantly by 42 and 26%, respectively, when all the other covariates remained constant.

Discussion

The purpose of this study was to evaluate the use pattern of migraine prescription drugs and its effect on the health care costs in patients enrolled in an employer-based health care program. Our study results indicated that nearly 45% of the patients with diagnosis of migraine did not receive appropriate pharmacotherapy and that nearly 65% of the patients who received antimigraine medications did not have migraine diagnosis. This study also found that migraine medication costs were the major proportion of migraine-related costs in patients, but total cost saving was shown in the patients due to significantly decreased medical costs.

Table 3 showed that those not using antimigraine medications presented higher frequency of ED visits and total number of outpatient visits related to migraine. These results suggested that poor health outcomes and disease management would be expected in patients subsequent to medication initiation. In addition, using agents for migraine prophylaxis might be considered to manage the disease and control medical costs. Migraine prophylaxis is aimed at preventing frequent attacks, including migraine severity and length that often incurs high costs for pain relief, diagnostic services, and medical care. Wertz et al. [28] reported that headache-related resource utilization and costs were significantly lowered after initiation of preventive migraine treatment in a sample of a large managed-care population. Therefore, appropriate preventive therapy may reduce the disease burden and medical utilization.

Our study also suggests suboptimal migraine therapy, which is consistent with previous report. Among patients with migraine diagnosis, only 57% took antimigraine medications. Notably, although pharmacy cost was reduced without taking prescription drugs, total health care costs were increased due to heavy costs on medical utilization. Table 3 showed that those not using antimigraine drugs presented higher frequency of ED visits and total number of outpatient visits related to migraine. These results suggested that poor health outcomes and disease management...
might be associated with inadequate antimigraine medication use. Based on this evidence, there is a need to improve the quality of migraine care, and particularly provide physicians and patients with therapeutic options that are effective and well tolerated. Moreover, we also found that two-thirds of all patients in the study has

Table 2 Characteristics of the study population (n = 465)

| Variable                | All patients (n = 465) | Antimigraine drug users (n = 365) | No antimigraine drug users (n = 100) | p value |
|-------------------------|------------------------|-----------------------------------|-------------------------------------|---------|
| Age (years), mean (SD)  | 43.5 (10.9)            | 43.8 (10.9)                       | 42.3 (11.0)                         | 0.210   |
| Gender female, n (%)    | 433 (93.1)             | 338 (92.6)                        | 95 (95.0)                           | 0.402   |
| CGI, mean (SD)          | 2.4 (2.3)              | 2.4 (2.3)                         | 2.7 (2.2)                           | 0.150   |
| RI, mean (SD)           | 17.6 (10.5)            | 17.7 (10.3)                       | 17.5 (11.3)                         | 0.861   |
| Depression, n (%)       | 307 (66.0)             | 240 (65.8)                        | 67 (67.0)                           | 0.816   |
| Diagnosis of migraine, n (%) | 233 (50.1)          | 133 (36.4)                        | 100 (100)*                          | <0.001  |

*CGI* care gap index, *RI* risk index, *SD* standard deviation

* Patients who neither used antimigraine drugs nor had migraine diagnosis were not included in the study

Table 3 Medical utilization and health care costs of the study population by antimigraine medication use (n = 465)

| Variable                | Antimigraine drug users (n = 365) | No antimigraine drug users (n = 100) | p value |
|-------------------------|-----------------------------------|-------------------------------------|---------|
| All-cause medical utilization |                                   |                                    |         |
| Hospitalization, n (%)  | 39 (10.7)                         | 15 (15.0)                           | 0.233   |
| ED visits, n (%)        | 83 (22.7)                         | 35 (35.0)                           | 0.013   |
| Total number of outpatient visits, mean (SD) | 13.2 (11.9) | 15.3 (15.6) | 0.220   |
| Migraine-related medical utilization |                                   |                                    |         |
| Hospitalization, n (%)  | 0                                 | 3 (3.0)                             | <0.001  |
| ED visits, n (%)        | 14 (3.8)                          | 11 (11.0)                           | 0.005   |
| Total number of outpatient visits, mean (SD) | 0.8 (1.8)                   | 1.4 (1.2)                           | <0.001  |
| All-cause health care costs ($), mean (median) | 7,043.7 (1921.4) | 10,450.6 (3352.0) | 0.019   |
|                          | Pharmacy                          |                                    |         |
| Medical                 | 2,827.5 (1408.1)                 | 1,817.3 (753.1)                     | <0.001  |
| Total                   | 9,871.2 (4648.1)                 | 12,267.9 (5267.3)                   | 0.633   |
| Migraine-related costs ($), mean (median) | 149.3 (0) | 634.1 (100.3) | <0.001  |
|                          | Medical                           |                                    |         |
| Medical                 | 149.3 (0)                         | 634.1 (100.3)                       | <0.001  |
| Total                   | 516.1 (201.9)                     | 0                                   | <0.001  |
| Total                   | 665.4 (283.5)                     | 634.1 (100.3)                       | 0.001   |

*ED* emergency department, *SD* standard deviation

Table 4 Associations between health care costs and the use of antimigraine medications

| Independent variables | Estimated coefficient (SE) | Dependent variable: log (total all-cause health care costs) | Dependent variable: log (all-cause medical costs) | Dependent variable: log (total migraine-related costs) |
|-----------------------|----------------------------|-----------------------------------------------------------|-------------------------------------------------|------------------------------------------------------|
| Antimigraine medication use (yes vs. no) | -0.30 (0.12)**             | -0.55 (0.17)**                                             | 0.62 (0.18)**                                    |
| Diagnosis of migraine (yes vs. no)        | -0.30 (0.10)**             | -0.37 (0.14)**                                             | 1.17 (0.15)**                                    |
| Age (years)                        | -0.01 (0.28)*              | -0.02 (0.01)**                                             | 0.02 (0.01)**                                    |
| Gender (female vs. male)           | 0.21 (0.18)                | 0.17 (0.23)                                               | -0.15 (0.25)                                     |
| CGI                                 | 0.05 (0.02)*               | 0.05 (0.03)                                               | 0.05 (0.03)                                      |
| RI                                  | 0.08 (0.01)**              | 0.08 (0.01)**                                             | 0.01 (0.01)                                      |
| Comorbid depression (yes vs. no)     | 0.15 (0.10)                | 0.19 (0.13)                                               | 0.04 (0.14)                                      |

*CGI* care gap index, *RI* risk index, *SE* standard error

* p < 0.05, ** p < 0.01, *** p < 0.001
depression diagnosis or used antidepressant medications. Studies showed that depression and migraine are highly correlated and might be bidirectional. That is, migraine may cause psychiatric conditions, vice versa or both [23, 29]. Both of the diseases significantly decrease health-related quality of life [8]. Thus, assessing depressive disorders in migraine patients may augment migraine care quality.

These findings, derived from employer-sponsored claims data, suggested antimigraine medication use may be associated with reduced total medical utilization and health care costs. The study results indicate opportunities to understand self-reported care and needs of employees with headache. We may further investigate migraineurs’ quality of lives and productivity via survey tools. Informed by the results of this study, we may develop intervention strategies to mitigate both direct (health care plan costs) and indirect (loss productivity and absenteeism) cost. More importantly, our results indicate a manner to improve migraine care, thereby increasing employees’ the quality of care via treatment optimization and targeted implementation.

Although this study provides evidence regarding the associations among antimigraine medication use, diagnosis of migraine, and resource utilization, we concede some study limitations. First, the retrospective cross-sectional study design restricts the ability to establish causal inferences related to antimigraine medication use. Second, some of these patients could use over-the-counter (OTC) medications instead of prescription drugs to manage the headache, subsequently biasing our claims-based analyses. Additionally, some patients receiving antimigraine medications without migraine diagnosis code could occur in the administrative data. Third, we used a diagnosis of depression or antidepressant medication use as a comorbid depression. It is possible that some of these patients received antidepressant agents for the treatment of conditions other than depression. Finally, the claims data provide information on prescribing patterns only rather than on actual medication use. Therefore, we suggest further investigations include patient self-reported medication use using a survey tool.

Conclusions

Noted limitations notwithstanding, the study results suggest inadequate pharmacotherapy in migraine treatment. After controlling for covariates, antimigraine prescription drug use was associated with lower total medical utilization and health care costs. This suggests appropriately managing a specific chronicity, potentially inflating disease-specific expenditures, can favorably impact total health care costs. Further studies should investigate patient self-reported care and needs to manage headache and develop effective intervention to improve patient quality of life and productivity.

Acknowledgments The Authors acknowledge the support of Francesca Holzheimer, the dedicated advisor at The Advisory Board Company (Washington D.C., US), for data analysis.

Conflict of interest The authors declared that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF (2002) Migraine in the United States: Epidemiology and patterns of health care use. Neurology 58:885–894
2. Lipton RB, Stewart WF, Diamond S, Diamonds ML, Reed M (2001) Prevalence and burden of migraine in the United States: Data from the american migraine study II. Headache 41:646–657
3. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American migraine prevalence and prevention study. Headache 47:355–363
4. Stang PE, Osterhaus JT (1993) Impact of migraine in the United States: Data from the national health interview survey. Headache 33:29–35
5. Lipton RB, Stewart WF, von Korff M (1997) Burden of migraine: Societal costs and therapeutic opportunities. Neurology 48:S4–S9
6. Landy SH, Runken MC, Bell CF, Higbie RL, Haskins LS (2011) Assessing the impact of migraine onset on work productivity. J Occup Environ Med 53:74–81
7. Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: Epidemiology and disease burden. Curr Pain Headache Rep 15:70–78
8. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, quality of life, and depression: A population-based case-control study. Neurology 55:629–635
9. Smith TR, Nicholson RA, Banks JW (2010) Migraine education improves quality of life in a primary care setting. Headache 50:600–612
10. Mennini FS, Gatto L, Martelletti P (2008) Improving care through health economics analyses: Cost of illness and headache. J Headache Pain 9:199–206
11. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 159:813–818
12. Goldberg LD (2005) The cost of migraine and its treatment. Am J Manag Care 11:S62–S67
13. Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology 71:559–566
14. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS (2005) Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43:521–530
15. Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R (2011) Medical utilization and costs associated with statin adherence in
16. Aubert RE, Yao J, Xia F, Garavaglia SB (2010) Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care 16:459–466
17. Simpson RJ, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A (2009) Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc 84:1065–1072
18. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT (2003) Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 25:2958–2971
19. Fishman P, Black L (1999) Indirect costs of migraine in a managed care population. Cephalalgia 19:50–57 (discussion 1)
20. Lofland JH, Frick KD (2006) Workplace absenteeism and aspects of access to health care for individuals with migraine headache. Headache 46:563–576
21. Stewart WF, Wood GC, Razzaghi H, Reed ML, Lipton RB (2008) Work impact of migraine headaches. J Occup Environ Med 50:736–745
22. Louter MA, Veen G, Ferrari MD, Zitman FG, Terwindt GM (2010) Migraine and depression should be treated concurrently. Ned Tijdschr Geneeskd 154:A1044
23. Frediani F, Villani V (2007) Migraine and depression. Neurol Sci 28(Suppl 2):S161–S165
24. Gautam S, Singh S (2008) Predicting overall and impactable future cost with the D2Hawkeye risk modeling system. http://www.d2hawkeyeservices.com. Accessed 12 November 2010
25. Clouse JC, Osterhaus JT (1994) Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 28:659–664
26. McCaig LF, Burt CW (2004) National hospital ambulatory medical care survey: 2002 emergency department summary. Adv Data 340:1–34
27. McCaig LF, Nawar EW (2006) National hospital ambulatory medical care survey: 2004 emergency department summary. Adv Data 372:1–29
28. Wertz DA, Quimbo RM, Yaldo AZ, Rupnow MF (2009) Resource utilization impact of topiramate for migraine prevention in the managed-care setting. Curr Med Res Opin 25:499–503
29. Sheftell FD, Atlas SJ (2002) Migraine and psychiatric comorbidity: From theory and hypotheses to clinical application. Headache 42:934–944